| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $9.8M | +172.1% |
| SG&A Expense | $6.5M | +9.5% |
| Pre-tax Income | -$15.8M | -76.3% |
| Net Income | -$15.8M | -76.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.8M | +5.4% |
| Short-term Investments | $14.9M | +43.1% |
| Current Assets | $20.0M | +34.0% |
| Total Assets | $20.4M | +29.8% |
| Current Liabilities | $5.5M | +32.7% |
| Total Liabilities | $7.3M | +11.8% |
| Stockholders' Equity | $13.1M | +42.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$13.5M | -72.3% |
| Investing Cash Flow | -$4.3M | -126.5% |
| Financing Cash Flow | $18.0M | +64.2% |